Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KY1005 in moderate to severe atopic dermatitis
NCT03754309Phase 2Completed
- Sponsor
- Kymab
- Start
- Dec 2018
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of amlitelimab in atopic dermatitis (AD), sponsored by Kymab. Started Dec 2018; status: completed.
02
Drugs
amlitelimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03754309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03754309.